meningococcal group A, C, W-135 and Y conjugate vaccine

This medicine is authorised for use in the European Union.


This is a summary of the European public assessment report (EPAR) for Menveo. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Menveo.

This EPAR was last updated on 06/07/2023

Authorisation details

Product details
Agency product number
Active substance
meningococcal group A, C, W-135 and Y conjugate vaccine
International non-proprietary name (INN) or common name
meningococcal group A, C, W-135 and Y conjugate vaccine
Therapeutic area (MeSH)
  • Immunization
  • Meningitis, Meningococcal
Anatomical therapeutic chemical (ATC) code
Publication details
Marketing-authorisation holder
GSK Vaccines S.r.l.
Date of issue of marketing authorisation valid throughout the European Union
Contact address
via Fiorentina 1
53100 Siena

Product information

21/06/2023 Menveo - EMEA/H/C/001095 - IB/0118

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.


Product information documents contain:

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

Bacterial vaccines

Therapeutic indication


Menveo is indicated for active immunisation of children (from two years of age), adolescents and adults at risk of exposure to Neisseria meningitidis groups A, C, W135 and Y, to prevent invasive disease.

The use of this vaccine should be in accordance with official recommendations.

Assessment history

Changes since initial authorisation of medicine

Related content

How useful was this page?

Add your rating
1 rating
2 ratings